We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSALV
RNS Number : 2585U
SalvaRx Group plc
23 October 2017
23 October 2017
SalvaRx Group plc
("SalvaRx" or the "Company")
Further Subscriptions for SalvaRx Limited Loan Facility
SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces further subscriptions for the SalvaRx Limited Loan Facility.
The Company announced on 2 March 2017 that its BVI subsidiary, SalvaRx Limited, had constituted up to US$5 million of unsecured loan notes in order to evaluate and either invest in or acquire further assets in the immuno-oncology sector (the "Loan Notes"). The Loan Notes are repayable on the fourth anniversary following issue and carry a coupon of 7% per annum. In addition, holders of Loan Notes will receive warrants to subscribe for new shares in SalvaRx Limited (the "Warrants"). US$7,500 of Warrants will be issued in respect of each US$10,000 loan note unit. The Warrants will vest in the event of a qualifying transaction (being a transaction or series of transactions whereby SalvaRx Limited obtains additional external equity financing in excess of US$15 million ("Qualifying Event") over a defined period). Further details of the Qualifying Event and pricing of the Warrants are described in the Company's announcement on 2 March 2017.
Mr Mellon and Dr Bailey, who are both directors and substantial shareholders in the Company, have each subscribed for an additional US$0.5 million of the Loan Notes. These additional subscriptions take their holdings of Loan Notes to US$1.5 million each.
In total, SalvaRx Limited has now issued approximately US$4 million of Loan Notes.
Ian Walters, CEO of SalvaRx, said "SalvaRx has now built its pipeline to ten programmes. With this further support from Jim Mellon and Greg Bailey we are able to continue to progress the various development programmes as we continue to assess other fundraising options."
Related Party Transactions
The subscription for the Loan Notes by, and associated grant of Warrants to, Mr Mellon and Dr Bailey constitute related party transactions under Rule 13 of the AIM Rules for Companies. The independent directors, being Ian Walters, Kam Shah, Richard Armstrong and Colin Weinberg, consider, having consulted with Northland Capital Partners Limited, the Company's Nominated Adviser, that the terms of the Loan Notes and the related Warrants are fair and reasonable insofar as the Company's shareholders are concerned.
-Ends-
SalvaRx Group plc Ian Walters (Chief Executive) Tel: +1 203 441 5451 Northland Capital Partners Limited Tel: +44 (0) 20 Nominated Adviser and Broker 3861 6625 Matthew Johnson / Edward Hutton (Corporate Finance) John Howes (Corporate Broking) Peterhouse Corporate Finance Limited Tel: +44 (0) 20 Joint Broker 7469 0932 Lucy Williams / Duncan Vasey
For more information please visit: www.salvarx.io
This information is provided by RNS
The company news service from the London Stock Exchange
END
FURMMBFTMBTTBLR
(END) Dow Jones Newswires
October 23, 2017 02:00 ET (06:00 GMT)
1 Year Salvarx Chart |
1 Month Salvarx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions